Insider Transactions in Q1 2025 at Aquestive Therapeutics, Inc. (AQST)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,182
-0.73%
|
$4,364
$2.54 P/Share
|
|
Mar 10
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,572
-1.31%
|
$9,144
$2.54 P/Share
|
|
Mar 09
2025
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,998
-5.05%
|
$107,996
$2.65 P/Share
|
|
Mar 09
2025
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
7,681
-2.47%
|
$15,362
$2.65 P/Share
|
|
Mar 09
2025
|
Lori J Braender Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,658
-2.58%
|
$21,316
$2.65 P/Share
|
|
Mar 09
2025
|
A Ernest Toth Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,736
-2.51%
|
$17,472
$2.65 P/Share
|
|
Mar 09
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,997
-2.62%
|
$15,994
$2.65 P/Share
|
|
Mar 09
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,431
-4.24%
|
$30,862
$2.65 P/Share
|
|
Mar 07
2025
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,307
-2.67%
|
$58,614
$2.65 P/Share
|
|
Mar 07
2025
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
272,000
+19.85%
|
-
|
|
Mar 07
2025
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
6,624
-2.09%
|
$13,248
$2.65 P/Share
|
|
Mar 07
2025
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+20.12%
|
-
|
|
Mar 07
2025
|
Lori J Braender Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,592
-2.27%
|
$19,184
$2.65 P/Share
|
|
Mar 07
2025
|
Lori J Braender Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+20.63%
|
-
|
|
Mar 07
2025
|
Sherry Korczynski SVP Sales and Marketing |
SELL
Payment of exercise price or tax liability
|
Direct |
5,428
-3.29%
|
$10,856
$2.65 P/Share
|
|
Mar 07
2025
|
Sherry Korczynski SVP Sales and Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+35.29%
|
-
|
|
Mar 07
2025
|
Carl N Kraus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,115
-2.52%
|
$16,230
$2.65 P/Share
|
|
Mar 07
2025
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+17.87%
|
-
|
|
Mar 07
2025
|
A Ernest Toth Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,193
-2.84%
|
$20,386
$2.65 P/Share
|
|
Mar 07
2025
|
A Ernest Toth Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+23.49%
|
-
|
|
Mar 07
2025
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,361
-2.35%
|
$14,722
$2.65 P/Share
|
|
Mar 07
2025
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+20.35%
|
-
|
|
Mar 07
2025
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,859
-3.42%
|
$25,718
$2.65 P/Share
|
|
Mar 07
2025
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+23.4%
|
-
|